What is Vertex's primary business strategy?

Vertex's strategy is to discover, develop, and commercialize novel small molecule drugs. They pursue a two-pronged approach: developing certain products independently for high-value markets and collaborating with pharmaceutical partners to develop and market other discovered products.

What are the key products or drug candidates mentioned in the filing?

The filing mentions Vertex's first marketed product, Agenerase (amprenavir), an HIV protease inhibitor. A significant focus is on 908 (VX-175), an HIV protease inhibitor with a pending NDA. Other key candidates in development include merimepodib (VX-497) for Hepatitis C, VX-148 for psoriasis, VX-702 for inflammatory diseases and acute coronary syndromes, and pralnacasan (VX-740) for rheumatoid arthritis and osteoarthritis.

What is Vertex's financial performance as of year-end 2002?

For the year ended December 31, 2002, Vertex reported total revenues of $161.1 million and a net loss of $108.6 million. However, the company maintained a strong financial position with $635 million in cash, cash equivalents, and marketable securities.

What are the major collaborations Vertex has in place?

Vertex has significant collaborations with GlaxoSmithKline (HIV protease inhibitors), Novartis (kinase inhibitors), Aventis (ICE inhibitors for inflammation), and Serono (caspase inhibitors). These partnerships are critical for funding research, development, and commercialization efforts.

VRTX 10-K FY2002 Annual Report — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed its 10-K for the fiscal year ended December 31, 2002, on March 31, 2003. The company is a biotechnology firm focused on discovering, developing, and commercializing small molecule drugs for significant unmet medical needs, including viral diseases, cancer, autoimmune disorders, and neurological conditions. The report highlights Vertex's proprietary, genomics-based drug discovery platform and its strategy of developing some drugs independently while partnering on others. A key point for investors is the impending regulatory decision on 908 (VX-175), an HIV protease inhibitor developed with GlaxoSmithKline, for which a New Drug Application (NDA) was filed with the FDA. The company also reported progress in its internal development pipeline, with several drug candidates in various stages of clinical and preclinical development, notably in areas like Hepatitis C, inflammation, and genetic disorders. The financial overview indicates that Vertex is still operating at a loss, a common characteristic of biotechnology companies in the development phase. However, the company maintained a strong cash position, bolstered by collaborative agreements and royalty revenues from its first marketed product, Agenerase. The report details significant research and development expenditures aimed at advancing its pipeline. Investors should note the company's ongoing reliance on partnerships for funding and market access, as well as the inherent risks associated with drug development, regulatory approvals, and market competition.

Key Highlights

1Vertex has 15 drug candidates in clinical or preclinical development across various therapeutic areas, including infectious diseases, inflammation, autoimmune disorders, cancer, neurological, and genetic diseases.

2A New Drug Application (NDA) for 908 (VX-175), an HIV protease inhibitor developed with GlaxoSmithKline, was filed with the FDA, with a potential U.S. launch anticipated in Q4 2003.

3The company is advancing two independent development programs for Hepatitis C virus (HCV) infection: merimepodib (VX-497) in Phase II and VX-950 in preclinical development.

4Vertex has a strong focus on inflammatory and autoimmune diseases, with candidates like VX-148 (psoriasis) and VX-702 (acute coronary syndromes) in clinical trials.

5Collaborations with major pharmaceutical companies like Novartis, GlaxoSmithKline, and Aventis are crucial for funding research and development and providing market access.

6The company reported total revenues of $161.1 million for 2002, with a net loss of $108.6 million.

7Vertex ended 2002 with a strong cash and marketable securities position of $635 million, providing runway for continued R&D investment.

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2002

Summary

Key Highlights

Frequently Asked Questions